Please try another search
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma. The company was incorporated in 2002 and is based in Hørsholm, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Peter Agre | - | - | Scientific Advisor |
Jørgen Frøkiær | - | - | Scientific Advisor |
Simon C. Robson | - | - | Scientific Advisor |
Lars Rosenkrantz Gundorph | 64 | 2023 | Director |
Peter Vilmann | 72 | 2023 | Independent Director |
Christian Vinding Thomsen | 49 | 2023 | Chairman of the Board |
Omar S. Qandeel | 63 | 2023 | Independent Director |
Martin Engell-Rossen | 49 | 2023 | Vice Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review